A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2002
10/09/2002	EP1246692A1 Templating of solid particles by polymer multilayers
10/09/2002	EP1246648A2 Dendrimer-photosensitizer complexes for medical applications
10/09/2002	EP1246645A2 A stable immunogenic composition for frozen storage
10/09/2002	EP1246641A2 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
10/09/2002	EP1246639A2 Glp-2 formulations
10/09/2002	EP1246630A1 Compositions and methods for facilitating skin growth and managing skin conditions
10/09/2002	EP1246629A1 Methods of using electron active compounds for managing cancer
10/09/2002	EP1246627A2 Polyanhydrides with biologically active degradation products
10/09/2002	EP1246622A1 Novel substituted benzimidazole dosage forms and method of using same
10/09/2002	EP1246616A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use
10/09/2002	EP1246615A2 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
10/09/2002	EP1246609A2 Micronized freeze-dried particles
10/09/2002	EP1246608A1 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
10/09/2002	EP1246597A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
10/09/2002	EP1246538A1 Thickened oil compositions of edible oil
10/09/2002	EP1077681B1 Pharmaceutical preparation containing levothyroxine sodium
10/09/2002	EP1066029B1 Peroral active agent suspension
10/09/2002	EP1039909B1 Method of production and composition of an oral preparation of itraconazole
10/09/2002	EP0904061B1 Pharmaceutical composition with base of rhein or diacerhein with improved biological availability
10/09/2002	EP0651993B1 Percutaneously administrable base composition and drug composition prepared therefrom
10/09/2002	CN1373753A Mutual salt of amlodipine and atorvastatin
10/09/2002	CN1373675A Composition for IVF
10/09/2002	CN1373674A Pourable liquid vehicles
10/09/2002	CN1373673A Stable medicinal composition for oral use
10/09/2002	CN1373669A Hybrid polypeptides with enhanced pharmacokinetic properties
10/09/2002	CN1373668A Hybrid peptide modulate immune response
10/09/2002	CN1373667A Formulations for parenteral use of estramustine phosphate and amino acids
10/09/2002	CN1373665A Pharmaceutical solutions for levosimendan
10/09/2002	CN1373659A Solid lipid formulations
10/09/2002	CN1373658A Method for making granules with masked taste and instant release of active particle
10/09/2002	CN1373657A Method for controlled production of ultrafine microparticles and nanoparticles
10/09/2002	CN1373656A Dispersion formulations contg. lipase inhibitors
10/09/2002	CN1372975A Carrier of exterior-applied medicines and its preparing process
10/09/2002	CN1372922A Multilayer emulsion for stabilization of effective component on dermatology and externally used preparation using it
10/08/2002	USRE37872 Enzymes
10/08/2002	US6462237 Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
10/08/2002	US6462081 5-thia-ω-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient
10/08/2002	US6462057 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
10/08/2002	US6462033 Topical mixture
10/08/2002	US6462022 Lisinopril compositions having large-particle DCPD
10/08/2002	US6461851 High expression modules containing two or more tandem copies of a methioninase encoding sequence
10/08/2002	US6461849 Modified polypeptide
10/08/2002	US6461643 Consists of at least one biologically- active agent; (b) at least one carrier comprising an acylated aldehyde of an amino acid, an acylated ketone of an amino acid, an acylated aldehyde of a peptide, an acylated ketone of a peptide
10/08/2002	US6461642 Crystallization using supercritical or subcritical fluids
10/08/2002	US6461641 Adding to bioactive agent polymeric vehicle which gels or solidifies at time of or shortly after injection and has consistency and density to displace cells and to retain bioactive agent at injection site, thereby enhancing delivery
10/08/2002	US6461636 Matrix mass containing (meth)acrylate copolymer having ammonio groups or mixture of (meth)acrylate copolymer having amino groups with one having carboxyl groups, propylene glycol and pergolide surrounded by larger plaster for fixing to skin
10/08/2002	US6461631 Biodegradable polymer composition
10/08/2002	US6461628 Non-woven keratin cell scaffold
10/08/2002	US6461617 Recombinant toxin fragments
10/08/2002	US6461607 Probiotic, lactic acid-producing bacteria and uses thereof
10/08/2002	US6461605 Continuous low-dose cytokine infusion therapy
10/08/2002	US6461603 Ester or amide linkage hydrolyzes to liberate artelinic acid; to treat malaria
10/08/2002	US6461602 Water-soluble, nontoxic prodrugs having a hydrolyzable carbamate group coupling the drug or active ingredient to a modified polymer; insoluble drug released in vivo; drug delivery
10/08/2002	US6461600 Analgesic in cream carrier
10/08/2002	US6461591 Storage stability
10/08/2002	US6461590 Stabilized gas-supersaturated suspensions and methods for their delivery
10/08/2002	US6461586 Method of magnetic resonance focused surgical and therapeutic ultrasound
10/08/2002	US6461545 Method of solubilizing and encapsulating itraconazole
10/08/2002	CA2254145C Improved process to stabilize proteins
10/08/2002	CA2218074C Powdered pharmaceutical formulations having improved dispersibility
10/08/2002	CA2070672C Compound of medicinal ingredient and hyaluronic acid and process for producing the same
10/07/2002	WO2001076598A1 Stabilized pharmaceutical compositions containing calcium channel blockers
10/03/2002	WO2002077189A2 Glycosylation-resistant and nonglycosylated cyanovirins
10/03/2002	WO2002077074A1 Compounds for a controlled release of active compounds
10/03/2002	WO2002077036A2 Recombinant production of polyanionic polymers, and uses thereof
10/03/2002	WO2002077034A2 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
10/03/2002	WO2002077033A1 Antibodies against cancer
10/03/2002	WO2002077025A1 Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
10/03/2002	WO2002077003A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof
10/03/2002	WO2002077000A2 Macrocyclic oligosaccharide derivatives which form manoscale assemblies
10/03/2002	WO2002076508A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
10/03/2002	WO2002076506A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition
10/03/2002	WO2002076500A1 Vaccine for the treatment of tubercolosis and other intracellular infections diseases
10/03/2002	WO2002076497A2 Method and composition
10/03/2002	WO2002076495A1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
10/03/2002	WO2002076491A1 Liposome targeting of matrix metalloproteinase inhibitors
10/03/2002	WO2002076489A1 Serum albumin binding moieties
10/03/2002	WO2002076486A2 Histidine-rich glycoprotein
10/03/2002	WO2002076476A2 Prodrugs of anticancer agents employing substituted aromatic acids
10/03/2002	WO2002076474A1 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
10/03/2002	WO2002076469A1 A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
10/03/2002	WO2002076454A1 Method for treatment of cancer and compositions for use therein
10/03/2002	WO2002076448A1 Molecular conjugates for use in treatment of cancer
10/03/2002	WO2002076446A1 Esmolol formulation
10/03/2002	WO2002076442A1 Stable aqueous liquid preparation
10/03/2002	WO2002076441A1 Microemulsions as precursors to solid nanoparticles
10/03/2002	WO2002076433A1 Dental formulation
10/03/2002	WO2002076432A2 Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
10/03/2002	WO2002076431A1 Biodegradable triblock copolymers as drug solubilizing agents
10/03/2002	WO2002076428A1 Liposome composition for improved intracellular delivery of a therapeutic agent
10/03/2002	WO2002076426A2 Intravaginal drug delivery devices for the administration of an antimicrobial agent
10/03/2002	WO2002076425A2 Manufacturing dissolvable dosage forms
10/03/2002	WO2002076424A1 Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles
10/03/2002	WO2002076411A2 Dermatological agent for the treatment of skin trauma, especially in burn conditions
10/03/2002	WO2002076398A2 Improved forms of pharmaceutically active agents and method for manufacture thereof
10/03/2002	WO2002076394A2 Enzyme-based anti-cancer compositions and methods
10/03/2002	WO2002076392A2 Thermally reversible water in oil in water emulsions
10/03/2002	WO2002076376A2 A stable pharmaceutical composition of pravastatin
10/03/2002	WO2002076344A1 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
10/03/2002	WO2002076248A2 Customized therapeutics and in situ diagnostics

1 ... 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 ... 1712